ArticleFrontiers in cardiovascular medicine2026
Safety and feasibility of direct return to the ward after transcatheter aortic valve replacement: a prospective observational study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With increasing procedural volumes and improved safety, transcatheter aortic valve replacement (TAVR) programs are exploring strategies to streamline postoperative care. This study aimed to evaluate the safety and feasibility of direct return to the cardiovascular surgery ward after TAVR. Methods: This prospective observational study enrolled patients who underwent TAVR between January and April 2024 and were directly admitted to the cardiovascular surgery ward postoperatively if they met predefined criteria. A historical cohort of patients treated between January and December 2023 who met the same eligibility criteria but were admitted to the CICU served as the control group. Propensity score matching was used to ensure comparability between groups. The primary outcome was the composite early safety endpoint defined by Valve Academic Research Consortium-3 (VARC-3). Secondary outcomes included 30-day major complications (per VARC-3), mortality, readmission, postoperative delirium, unplanned ICU transfer, and postoperative length of stay. Results: Of the 168 patients who underwent TAVR between January and April 2024, 130 (77.4%) were directly transferred to the ward. In the historical cohort, 231 patients were included as controls. After propensity score matching, 95 patients were included in each group. The 30-day composite early safety event rate was 8.4% in the ward group and 11.6% in the CICU group (OR = 0.7, 95%CI: 0.3-1.7), with no significant difference. Secondary outcomes, including major complications, mortality, readmissions, postoperative delirium, and unplanned ICU transfers, were comparable between groups. Median postoperative length of stay was significantly shorter in the ward group (4 vs. 6 days; mean difference 1.9 days, 95%CI: 1.3-2.5). Conclusions: Direct ward transfer after TAVR appears safe and feasible in selected patients and is associated with a shorter hospital stays compared to routine CICU admission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.